Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Quoin Pharmaceuticals Ltd. (QNRX)

Quoin Pharmaceuticals Enters $-Free At-the-Market Share Sales Deal With Leerink Partners

Neutral Impact 3 of 5 financing Written later

Quoin Pharmaceuticals signed a sales agreement with Leerink Partners LLC that lets it sell American Depositary Shares from time to time through an at-the-market offering. Leerink would receive 3.0% of gross sale proceeds, and the filing does not state a dollar amount or number of shares to be sold, so the potential dilution to shareholders is not quantified.

Key points

  • Sales agreement with Leerink Partners LLC dated November 4, 2026; each ADS represents 35 ordinary shares.
  • Leerink Partners would be paid 3.0% of gross sale proceeds from ADSs sold through it.
  • Sales are made under Form S-3 (File No. 333-299668), declared effective November 4, 2026; the filing states no aggregate offering size.
  • Either party may suspend or terminate the agreement at any time upon notice.

The filing

CompanyQuoin Pharmaceuticals Ltd. (QNRX)
Form8-K, current report
Filed with the SECNov 4, 2026, 5:26 PM ET
Accession number0001104659-26-122790

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.